B. Chan

Pulmonary and Respiratory Medicine · with Hughes · 2015

A researcher in the Science corpus: 1 paper; trusts 5 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom B. Chan trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. William Pao
  2. M. Kris
  3. J. Engelman
  4. Vincent A. Miller
  5. Y. Yarden
  6. D. Hanahan
  7. M. Reck
  8. P. Jänne
  9. A. Chachoua
  10. L. Sequist

Papers from B. Chan's perspective

Ordered by how strongly the researchers B. Chan trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer (Nature)
  2. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib (Proceedings of the National Academy of Sciences of the United States of America)
  3. KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib (PLoS Medicine)
  4. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. (New England Journal of Medicine)
  5. Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors (Science Translational Medicine)
  6. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. (The Lancet)
  7. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. (Journal of Clinical Oncology)
  8. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. (Proceedings of the National Academy of Sciences of the United States of America)
  9. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy (Science)
  10. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. (Journal of the American Medical Association (JAMA))

Their papers